No material corporate announcements were identified for Gilead Sciences Inc. (GILD) in the 30 days preceding this report's generation date of 2026-09-27. Prior briefings dated 2026-09-19 and 2026-09-11 similarly noted an absence of discrete news events, with analysis in each case anchored to verified financial filings and transaction records. The absence of material press releases or regulatory disclosures in this window means recent coverage has been driven primarily by quantitative data sources [Brief - 2026-09-19] [Brief - 2026-09-11].
As of the quarter ending 2026-06-30, Gilead reported trailing twelve-month revenue of $30.46 billion, representing year-over-year growth of 10.18%. Gross margin stood at 64.95%, while operating margin was -8.20% and net margin was -10.64%, resulting in a net loss of $3.24 billion on a TTM basis. EPS declined 641.67% year-over-year. The company held $3.18 billion in cash against total debt of $28.66 billion. Market capitalisation was approximately $187.3 billion at the reporting date. No P/E ratio is calculable given the net loss position [SEC 10-Q - GILD - 2026-06-30].
Insider activity over the past 30 days comprised 19 transactions with a net selling direction and a net disposal value of approximately $3.10 million [SEC Form 4 - GILD - 2026-09]. On the institutional side, four notable new positions were initiated during the most recent 13F reporting period: Citadel opened a new position [SEC 13F - Citadel - Q2 2026], Millennium opened a new position [SEC 13F - Millennium - Q2 2026], AQR Capital opened a new position [SEC 13F - AQR Capital - Q2 2026], and Bridgewater opened a new position [SEC 13F - Bridgewater - Q2 2026]. These simultaneous initiations across multiple large institutional managers constitute the primary trigger for this report.
The prevailing macro environment features a 10-year US Treasury yield of 5.18% and a 2-year yield of 4.87%, producing a normal yield curve spread of 31 basis points [FRED DGS10] [FRED DGS2]. Elevated risk-free rates remain a relevant backdrop for large-cap pharmaceutical companies carrying substantial debt loads, as financing costs and debt servicing dynamics are directly influenced by prevailing interest rate levels.